Key facts
- It has raised $13.8M; the latest was Accelerator/Incubator in Feb 2025.
- Notable investors include Gaingels, Calm Ventures, Possible Ventures, Startmate, Main Sequence Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Xylo Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Xylo Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xylo Bio
Developer of a psychedelic therapeutic platform designed to rewire neural circuits and restore brain function. The company offers novel, non-hallucinogenic, rapid-acting medicines for psychiatric and neurological disorders, enabling doctors to optimize treatments and transform care for patients with neurological and psychiatric conditions.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2021
- Employees
- 33
- Website
- xylo.bio/
- Ownership
- Privately Held (backing)
Xylo Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xylo Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xylo Bio in its N-PORT filings yet. We sweep new filings monthly.